Literature DB >> 172233

The enzymatic basis of the selective action of cyclophosphamide.

P J Cox, B J Phillips, P Thomas.   

Abstract

The initial metabolic products of cyclophosphamide (4-hydroxy-cyclophosphamide and aldophosphamide) were prepared biologically in unpurified form. Their toxicity to tumor cells were tested by bioassay techniques and in cell culture, and the deactivation abilities of various tissue-soluble fractions were quantitated. Liver and kidney cytosol effectively deactivated the primary metabolites, whereas cytosols from gastrointestinal tract mucosa, Walker ascites tumor, and spleen were less efficient. When [14C]cyclophosphamide was activated and incubated with liver cytosol, 34% of all radioactivity was identified as carboxyphosphamide, by mass spectrometry of the methyl ester. Measurement of alcohol dehydrogenase (EC 1.1.1.1) and aldehyde dehydrogenase (EC 1.2.1.3) activities by reduced nicotinamide adenine dinucleotide production revealed a qualitative correspondence between aldehyde dehydrogenase activity and deactivation ability. Unpurified aldophosphamide and the analogs prepared from 6-methyl- and 5,5-dimethylcyclophosphamides were substrates for nicotinamide adenine dinucleotide-requiring enzymes, whereas incubation of 4-hydroxy-4-methylcyclophosphamide in an unfractionated incubation mixture with liver soluble enzymes did not cause reduced nicotinamide adenine dinucleotide production.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 172233

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  15 in total

1.  A curative combination cancer therapy achieves high fractional cell killing through low cross-resistance and drug additivity.

Authors:  Adam C Palmer; Christopher Chidley; Peter K Sorger
Journal:  Elife       Date:  2019-11-19       Impact factor: 8.140

2.  Formation, toxicity and inactivation of acrolein during biotransformation of cyclophosphamide as studied in freshly isolated cells from rat liver and kidney.

Authors:  Y Ohno; K Ormstad
Journal:  Arch Toxicol       Date:  1985-06       Impact factor: 5.153

3.  The effect of cimetidine on cyclophosphamide metabolism in rabbits.

Authors:  L B Anthony; Q C Long; R F Struck; K R Hande
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

4.  Cyclophosphamide metabolism in the primary immune organs of the chick: assays of drug activation, P450 expression, and aldehyde dehydrogenase.

Authors:  R R Misra; N A Lorr; S E Bloom
Journal:  Arch Toxicol       Date:  1991       Impact factor: 5.153

5.  Targeting colorectal cancer with small-molecule inhibitors of ALDH1B1.

Authors:  Zhiping Feng; Marisa E Hom; Thomas E Bearrood; Zachary C Rosenthal; Daniel Fernández; Alison E Ondrus; Yuchao Gu; Aaron K McCormick; Madeline G Tomaske; Cody R Marshall; Toni Kline; Che-Hong Chen; Daria Mochly-Rosen; Calvin J Kuo; James K Chen
Journal:  Nat Chem Biol       Date:  2022-07-04       Impact factor: 16.174

6.  Comparative in vitro cytotoxicity of cyclophosphamide, its major active metabolites and the new oxazaphosphorine ASTA Z 7557 (INN mafosfamide).

Authors:  D S Alberts; J G Einspahr; R Struck; G Bignami; L Young; E A Surwit; S E Salmon
Journal:  Invest New Drugs       Date:  1984       Impact factor: 3.850

7.  Ideas and reality in the development of cancer chemotherapeutic agents, with particular reference to oxazaphosphorine cytostatics.

Authors:  N Brock
Journal:  J Cancer Res Clin Oncol       Date:  1986       Impact factor: 4.553

8.  Cyclophosphamide-resistant Yoshida ascites tumor cells and their cross resistance to some alkylating agents.

Authors:  H H Gerhartz; E Liss; H Schmidt
Journal:  J Cancer Res Clin Oncol       Date:  1979-07-27       Impact factor: 4.553

9.  Metabolism of high doses of cyclophosphamide.

Authors:  R A Milsted; M Jarman
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

10.  Effects of the induction of hepatic microsomal metabolism on the toxicity of cyclophosphamide.

Authors:  H L Gurtoo; S K Bansal; Z Pavelic; R F Struck
Journal:  Br J Cancer       Date:  1985-01       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.